Publications
Detailed Information
Telmisartan to prevent recurrent stroke and cardiovascular events
Cited 557 time in
Web of Science
Cited 640 time in Scopus
- Authors
- Issue Date
- 2008-08-30
- Publisher
- Massachusetts Medical Society
- Citation
- N Engl J Med. 2008;359(12):1225-1237
- Keywords
- Aged ; Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use ; Benzimidazoles/adverse effects/*therapeutic use ; Benzoates/adverse effects/*therapeutic use ; Blood Pressure/drug effects ; Cardiovascular Diseases/epidemiology/mortality/*prevention & control ; Creatinine/blood ; Diabetes Mellitus/epidemiology ; Female ; Follow-Up Studies ; Heart Failure/epidemiology/prevention & control ; Humans ; Kaplan-Meiers Estimate ; Male ; Middle Aged ; Myocardial Infarction/epidemiology/prevention & control ; Potassium/blood ; Recurrence/prevention & control ; Stroke/*drug therapy/prevention & control ; Treatment Failure
- Abstract
- BACKGROUND: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke. METHODS: In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes. RESULTS: The median interval from stroke to randomization was 15 days. During a mean follow-up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P=0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P=0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P=0.10). CONCLUSIONS: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)
- ISSN
- 1533-4406 (Electronic)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18753639
http://content.nejm.org/cgi/reprint/359/12/1225.pdf
https://hdl.handle.net/10371/68343
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.